Shortening radiation targets for stage 3 lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether focusing radiation only on the main tumor (not the surrounding area) is safe and effective for people with stage 3 lung cancer that cannot be removed with surgery. It aims to reduce side effects while keeping the treatment working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 3A or 3B non-small cell lung cancer that cannot be removed with surgery.
- You are between 18 and 80 years old.
- Your overall health is good (able to do daily activities, ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within acceptable ranges.
- You have not had radiation therapy to the chest or chemotherapy for this cancer before.
- You are willing to use birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether giving focused radiation therapy to the main lung tumor, in addition to standard treatments like targeted therapy or chemo-immunotherapy, can help people with advanced lung cancer that has spread to many places. The goal is to see if adding this radiation can improve outcomes without causing too many side effects.
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
This trial tests whether combining two immunotherapy drugs (which help your immune system fight cancer) with a type of precisely targeted radiation (SBRT) is safe and effective for people with early-stage non-small cell lung cancer. If you qualify, you might receive a treatment that could boost your body's ability to destroy cancer cells.
This study tests if adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy and specially planned radiation works better for stage 3 lung cancer that cannot be surgically removed. It may be an option if you have not had previous treatment for this cancer.
This trial is for people with advanced non-small cell lung cancer whose tumors responded well to initial chemo-immunotherapy. Instead of giving full chest radiation, doctors will only target the main tumor to see if it can prevent regrowth with fewer side effects.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.